EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut Microbiota and Metabolite Remodeling Underlies the Anxiolytic Effect of Anshen Bunao Oral Liquid

Yan Chen, Song Lei, Zhipeng Chen, Wenbo Gao, Gang Liu, Yongkuan Wang, Leqi Wang, Xiuyun Zhang, Xue Xiao, Qinqiang Long iD

Pharmaceuticals · 26.05.2026 · 19 (6) · 831

DOI: 10.3390/ph19060831 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 26.05.2026. Verfasst von Yan Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation of Medical Science and Technology of Guangdong Province, Research Project of Chinese Medicine in TCM Bureau of Guangdong Province, Guangdong University Featured Innovation Program Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Anshen Bunao Oral Liquid (ABOL) is a traditional medicinal formula comprising Cornu Cervi Pantotrichum, Radix Polygoni Multiflori Preparata and other ingredients. It replenishes essence, nourishes qi and blood, and soothes the spirit. It is used in clinical practice to treat neurasthenia and insomnia (emotion-related symptoms), and its key component, glycyrrhizin, exhibits anxiolytic properties. This aligns with the holistic approach of traditional Chinese medicine (TCM) to regulating neuropsychiatric disorders. The aim of this study is to evaluate the anxiolytic efficacy of ABOL in rats with anxiety induced by chronic restraint stress (CRS), and to clarify its mechanism by focusing on modulation of the gut–brain axis (microbiota and metabolism).

Methods

Sprague-Dawley rats underwent three hours of restraint per day for 28 days to induce anxiety. ABOL was administered intragastrically in three doses. Anxiety-like behaviours were assessed using OFT, EPM and SPT. Serum, tissue and faecal samples were analysed using ELISA, histopathology, immunohistochemistry, non-targeted metabolomics, 16S rRNA sequencing and RT-qPCR.

Results

CRS induced anxiety-like behaviours, impaired weight gain and perturbed the balance of neurotransmitters (decreasing 5-HT, GABA, NE and DA, while increasing CORT), inducing inflammation/oxidative stress, hippocampal neuronal injury, intestinal barrier dysfunction and gut microbiota/metabolic dysregulation. ABOL effectively reversed these abnormalities by restoring the balance of neurotransmitters and the HPA axis, suppressing inflammation and oxidation, protecting neurons and the intestinal barrier, remodelling the gut microbiota (enriching Akkermansia and balancing Firmicutes/Bacteroidota) and regulating sphingolipid and glycerophospholipid pathways. The interaction between the gut microbiota and metabolites may contribute to this pharmacological effect.

Conclusions

ABOL exerts anxiolytic effects by modulating the gut–brain axis at multiple targets, involving microbiota remodelling, regulation of lipid metabolism and improvement of pathology. This validates its ethnopharmacological value, linking traditional Chinese medicine to the development of modern anxiolytics.

Schlagwörter

Stichwörter der Autor:innen

Anshen Bunao oral liquidanxiety disorderschronic restraint stress (CRS)microbiomeuntargeted metabolomics

Autor:innen und Institutionen

  • Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China.
  • Jilin Aodong Yanbian Pharmaceutical Co., Ltd., Yanbian 133700, China.
  • Jiyuan Neurohealth Industry Research Institute of Guangdong Pharmaceutical University, Guangzhou 510006, China.

ORCID-Profile: Qinqiang Long

Förderung

  • Research Foundation of Medical Science and Technology of Guangdong Province
  • Research Project of Chinese Medicine in TCM Bureau of Guangdong Province
  • Guangdong University Featured Innovation Program Project

Zitieren

APA

Chen, Y., Lei, S., Chen, Z., Gao, W., Liu, G., Wang, Y., Wang, L., Zhang, X., Xiao, X., & Long, Q. (2026). Gut Microbiota and Metabolite Remodeling Underlies the Anxiolytic Effect of Anshen Bunao Oral Liquid. Pharmaceuticals, 19(6), 831. https://doi.org/10.3390/ph19060831

Vancouver

Chen Y, Lei S, Chen Z, Gao W, Liu G, Wang Y, et al. Gut Microbiota and Metabolite Remodeling Underlies the Anxiolytic Effect of Anshen Bunao Oral Liquid. Pharmaceuticals. 2026;19(6):831. doi:10.3390/ph19060831

BibTeX
@article{Chen2026,
  author = {Chen, Yan and Lei, Song and Chen, Zhipeng and Gao, Wenbo and Liu, Gang and Wang, Yongkuan and Wang, Leqi and Zhang, Xiuyun and Xiao, Xue and Long, Qinqiang},
  title = {Gut Microbiota and Metabolite Remodeling Underlies the Anxiolytic Effect of Anshen Bunao Oral Liquid},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {6},
  pages = {831},
  doi = {10.3390/ph19060831}
}
Kostenlos starten →